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Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving therapy for patients with malig-
nant and nonmalignant disease states. Transplant has been associated with high treatment-related morbidity
and mortality, therefore limiting its usefulness in patients with baseline liver dysfunction. In the event that a
patient with hepatic insufﬁciency is selected for HSCT, dosage adjustments may be considered; however, no
reliable endogenous biomarkers can serve as a guide for adjustments. There is no clear standard or guideline
for how to approach these patients, and most adjustments are made empirically on the basis of expert
opinion. This article offers practical advice and outlines our personal approaches to provide dosing recom-
mendations for commonly-used preparative agents in the setting of hepatic impairment with the aim to
optimize dosing for this patient population.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION transplant and have been found to have an increased mor-
Hematopoietic stem cell transplantation (HSCT) is
considered to be a potentially life-saving therapy for patients
with certain malignant and nonmalignant disease states. In
the early days of transplant, treatment-related mortality was
high due to infectious complications, organ damage, and
graft-versus-host disease (GVHD) [1]. Changes in practice to
use less-toxic conditioning regimens for patients with
comorbidities have substantially reduced the incidence of
treatment-related mortality despite the fact that trans-
plantation is being offered to patients who are older and
more seriously ill. Although the overall prevalence of liver
complications in the general population has been decreased
in recent decades, patients with hepatic impairment may
still occasionally present for transplant evaluation [2].
Transplant candidates may present with varying degrees
of liver dysfunction due to chronic hepatitis, cirrhosis, or
cholestasis [2]. Alternatively, patients may have damage to
the liver as a result of previous chemotherapy, or damage
may be directly related to their speciﬁc neoplastic process
[3]. Historically, patients with severe hepatic dysfunction,
including those with marginally-compensated cirrhosis
(Child-Pugh class B or C), have not been considered suitable
candidates for HSCT [4,5]. Reduced-intensity conditioning
regimens may lessen the potential for post-HSCT complica-
tions in patients with chronic liver disease; however, these
patients may still be at risk for decompensation afteredgments on page 628.
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Currently, no endogenous markers can accurately predict
hepatic drug clearance and serve as a guide for dosage ad-
justments for patients with baseline hepatic impairment
[3,6]. Without reliable biologic markers of liver metabolism
and clearance, there are several general approaches to pa-
tients with hepatic dysfunction when dosing chemotherapy
[7]. Analysis of the pharmacokinetics of the speciﬁc agent
may lead to generalizations about the likelihood of toxicity
when administered to a patient with chronic liver disease,
thus leading to empiric dose adjustments [7]. Dose adjust-
ments should be individualized based on speciﬁc indices of
liver dysfunction and subsequent pharmacokinetic alter-
ations; however, there is no clear guideline for dose opti-
mization in this patient population. Ideally, if published data
are available that analyze the pharmacokinetics of a given
chemotherapy agent in a patient population with hepatic
insufﬁciency, adjustments may be recommended based on
serum bilirubin, alanine aminotransferase (ALT), and alkaline
phosphatase levels [7]. Therapeutic drug monitoring (TDM)
in real time is another valid option, when available, because
drug concentrations may be altered based on patient-speciﬁc
metabolism [7].
PHARMACOKINETIC CONSIDERATIONS IN PATIENTS
WITH LIVER DISEASES
Optimal chemotherapy dosing for patients with chronic
hepatic impairment is still largely unknown due to difﬁ-
culties with balancing the need for systemic exposure versus
the potential for harm with narrow therapeutic windows
[3,7,8]. In addition, medications with primarily renal elimi-
nation may still prove problematic in cirrhotic patients whoSociety for Blood and Marrow Transplantation.
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normal serum creatinine value [6].
Hepatic insufﬁciency may lead to decreased metabolism
of certain antineoplastic agents that undergo hepatic bio-
transformation to either active metabolites or resulting in
detoxiﬁcation [3]. Cyclophosphamide (CY) requires activa-
tion to an alkylating metabolite by the liver and has no
intrinsic alkylating activity before biotransformation [9].
Patients with impaired liver function have a reduced
biotransformation rate, and accumulation may potentially
occur in this patient population [9]. An increase in adverse
events has not been observed in patients with impaired liver
function who receive CY; therefore, it may be inferred that
toxic effects are attributable to metabolites [10].
Reports in the published literature describe patients who
underwent successful allogeneic HSCT in the setting of he-
patic impairment [11]. However, the literature consists of
mostly case reports including patients with only moderate
liver dysfunction. In addition, administration guidelines have
focused on patients with liver cirrhosis or ﬁbrosis and not on
patients with increased transaminases and/or cholestasis
[12]. Therefore, the available pharmacokinetic data are far
from complete.
ASSESSMENT OF HEPATIC DYSFUNCTION
Before transplantation, evaluation of liver function should
aim to detect the presence of liver disease through patient
history, physical examination, and a comprehensive liver
panel including serum aspartate aminotransferase, ALT,
bilirubin, albumin, and prothrombin time [5]. Hepatitis
workup should include testing for hepatitis B e antigen, anti-
hepatitis B e antibody, and hepatitis B virus (HBV) DNA. The
level of HBV DNA should also be quantiﬁed, if positive [13].
Patients in whom liver dysfunction is identiﬁed should un-
dergo further workup, including liver imaging and biopsy, as
clinically indicated, to assess for the presence of ﬁbrosis or
cirrhosis [5,13]. Liver biopsy should also be considered if
there is clinical suspicion of cirrhosis or extensive ﬁbrosis,
especially when risk factors for cirrhosis are present [14]. If
cirrhosis is identiﬁed based on imaging  biopsy, myeloa-
blative conditioning regimens are strongly discouraged.
Patients with Cirrhosis
Patients with pre-existing cirrhosis or established hepatic
ﬁbrosis on biopsy are at high risk for severe sinusoidal
obstruction syndrome (SOS), multiorgan failure, and fatal
hepatic decompensation after transplantation, even with the
use of nonmyeloablative regimens [4,5,14,15]. By selecting
less liver-toxic agents for the conditioning regimen, the risk of
SOSmay be lessened and the chance for survival improves [4].
Myeloablative and reduced-intensity conditioning regimens
are typically considered to be contraindicated in patients with
minimally compensated cirrhosis because of the risk for post-
transplant liver complications [2,4,5]. For patients with well-
compensated cirrhosis, use of a nonmyeloablative regimen, a
regimen that does not contain a high dose of CY or total body
irradiation (TBI), or substituting a noneliver-toxic drug for CY
may all be valid approaches [14].
Patients with Hepatitis
Although the risk for hepatitis transmission through
blood products is quite small in the present day, many pa-
tients still present for transplantation with previous expo-
sure to hepatitis viruses [13]. Reactivation may be a late
complication of HSCT, rising by 9% to 13% per year of survivalafter transplantation, with a cumulative probability of 43% at
4 years after HSCT reported in one study [16]. It has been
reported that viremia may be triggered after corticosteroid
treatment for acute GVHD, antibody to hepatitis B, surface
antigenenegative serologic status of the donor, development
of chronic GVHD, and loss of protective native antibody to
hepatitis B surface antigen after HSCT [2,4,16,17].
Before transplantation, hepatitis viral serology and PCR
results should be evaluated to identify patients with hepa-
titis B or C infection. For patients with latent HBV infection
(anti-hepatitis B core antigen positive/HBV DNA-), HBV DNA
tests should be used to monitor for viremia [2]. In viremic
patients (HBV DNAor hepatitis B surface antigen positive),
prophylaxis should be initiated before transplant or upon
reactivation in patients with latent infection [2]. The ideal
agent either for prophylaxis or preemptive therapy is lam-
ivudine [7]. Lamivudine has been shown to be effective at
reducing the incidence of post-HBV as well as HBV exacer-
bations and should be continued for a minimum of 1 year
post-HSCT [14,18,19]. Additionally, lamivudine should not be
discontinued until all immunosuppressive agents have been
discontinued [15]. HBV-infected patients should also receive
HSCT from an HBV naturally immune donor, when possible
[8,14,20]. Post-transplant, patients at increased risk for HBV
reactivation based on independent predictors should
frequently undergo HBsAg, HBsAb, and HBV viral load
assessment to detect reactivation should it occur [16].
Most patients with hepatitis C viral infection who un-
dergo HSCT will develop chronic hepatitis; however, in the
ﬁrst 10 years after transplant, the liver-related morbidity is
typically minimal [4]. Long-term survivors with chronic
hepatitis C should be considered for antiviral therapy such as
interferon-alfa, which can be safely administered after
discontinuation of all immunosuppressive agents for a least
6 months if there is no evidence of GVHD or myelosup-
pression [13].
Patients with Ascites
Chemotherapy administration may prove problematic in
patients with pleural effusions or ascites [7,21]. Hydrophilic
agents, such as ﬂudarabine, may exhibit third spacing into
the ascitic ﬂuid, increasing the volume of distribution and
potentially resulting in prolonged drug exposure [7]. Maha-
devan et al. [21] reported a case of 1 patient who received
ﬂudarabine for treatment of follicular lymphoma in the
setting of pleural ﬂuid accumulation. This patient developed
neutropenia and associated septicemia 2 weeks after ﬂu-
darabine administration, presumably due to prolonged drug
exposure [21]. No data indicate that an empiric dosage
adjustment may be effective. In the setting of ascites,
draining of pleural ﬂuid or ascites is recommended before
ﬂudarabine administration. These patients should also be
closely monitored for prolonged toxicities due to the possi-
bility for drug accumulation [7,21].
POTENTIAL FOR LIVER TOXICITY POST-TRANSPLANT
Sinusoidal Obstruction Syndrome
Liver damage, including SOS, is a well-documented
complication post-transplant, developing in approximately
20% to 40% of patients receiving more toxic myelosup-
pressive regimens [8]. This potentially fatal complication
after HSCT consists of a variety of clinical and pathologic
ﬁndings including jaundice, ﬂuid retention, and painful he-
patomegaly [8,15]. Clinical criteria for a diagnosis of SOS have
been developed by both the Seattle and Baltimore groups
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events must occur within 20 days of transplant: hyper-
bilirubinemia (total serum bilirubin >2 mg/dL), hepato-
megaly or right upper quadrant pain of liver origin, and
sudden weight gain (>2% of baseline body weight) due to
ﬂuid accumulation. The ﬁrst 20 days was developed by the
Seattle group based around CY-containing regimens, and
that temporal range may be less applicable for other regi-
mens [8]. The Baltimore criteria include jaundice (bilirubin
2.0 mg/dL) and 2 of the following additional criteria: he-
patomegaly (usually painful), ascites, or 5% weight gain
[22,23]. The severity of SOS may range from mild to severe.
Mild SOS typically does not require treatment and resolves
completely, moderate SOS requires diuretics or pain medi-
cations, and severe SOS requires treatment but does not
resolve before death or day þ100 [3,8].
The incidence of SOS varies based on several factors,
including components of the conditioning regimen, treat-
ment intensity, concomitant drugs using during conditioning
therapy, and presence of liver disease at baseline [2]. Most
reduced-intensity conditioning regimens have a very mini-
mal incidence of SOS, whereas myeloablative regimens con-
taining CY dosed at 120 mg/kg plus TBI >14 Gy may have an
incidence as high as 50% [2]. However, the current incidence
of SOS at most centers has been reported to be 15% to 20% [3].
This decrease is largely attributable to the fact that TBI doses
>14 Gy are infrequently used, CY is commonly replaced with
ﬂudarabine, and TDM allows for more optimal levels of pre-
parative agents with narrow therapeutic indices [2]. Several
commonly used medications during the pre- and post-
transplant period may also contribute to the risk for SOS,
including azole antifungals, sirolimus, and methotrexate [2].
McDonald and Frieze [7] reported that elevated serum
transaminase levels before HSCT were highly correlated with
subsequent severe SOS (relative risk, 4.6). Patients with
greater transaminase elevations before HSCT were reported
to have a higher incidence of severe SOS than those with
minimal elevations [7]. Several other prospective studies
have also reported an association between pretransplant
transaminase elevations and subsequent development of
SOS [9,10,12]. These studies also reported a marginal statis-
tical signiﬁcance for correlation between severe SOS and a
remote history of hepatitis, drug-related liver injury, or
abdominal radiation therapy [7].
Preventative strategies may be used for patients at high
risk for SOS, including those with chronic liver disease;
however, the beneﬁts of current therapies are unproven [15].
At our institution, high-risk patients who undergo allogeneic
HSCT receive ursodiol 300 mg 3 times a day administered
starting 14 days before initiation of the conditioning
regimen. Antifungal prophylaxis with micafungin, which
does not undergo extensive hepatic metabolism, is used in
place of ﬂuconazole or voriconazole until engraftment, un-
less clinically indicated otherwise. Additionally, phenytoin is
switched to levetiracetam or benzodiazepines for seizure
prophylaxis if busulfan (BU) is including in the preparative
regimen. All other hepatotoxic medications are discontinued
if possible. To prevent ﬂuid overload, aggressive diuresis is
used when intake exceeds output with a goal weight change
of 2% to 5% from baseline by day 0 [15].
Fungal Liver Infections
Hepatic fungal infection may present with symptoms of
tender hepatomegaly, fevers, and abnormal liver enzyme
levels [2,13]. Antifungal prophylaxis is effective in preventingmost fungal infections post-transplant aside from candida
infections [2,4]. However, azole antifungal medications are
primarily metabolized through the CYP450 system, which
may create drug interactions with common conditioning
agents such as BU and CY [4]. Studies have shown increased
risk of liver function elevations with azoles when compared
with echinocandins [25,26]. In the setting of HSCT, mica-
fungin was found to have comparable efﬁcacy with ﬂucon-
azole in preventing proven or probable invasive fungal
infection (94% versus 88%; 95% conﬁdence interval, 5.4% to
17.4%; P ¼ .295) [27].
SEARCH OF RELEVANT PUBLICATIONS
A thorough search of relevant publications was per-
formed in PubMed and Medline, using the Mesh headings
and key words “hepatic insufﬁciency” and “hematopoietic
stem cell transplantation” or “bone marrow transplantation”
limited to publications in the English language with human
participants. Relevant publications were identiﬁed and
reviewed by the authors. In addition to the online search,
review of supporting references of included and excluded
articles was performed. Articles that did not include HCST
patients were excluded. Practice guidelines, editorials, and
laboratory studies with no clinical correlates were also
excluded.
Currently, there are a paucity of randomized trials eval-
uating preparative regimens for stem cell transplantation in
the population of patients with hepatic insufﬁciency and a
lack of published guidelines on the topic. Therefore, this
article aims to offer practical advice and outlines our per-
sonal approaches to treatment. The aim of this review is to
critically analyze available literature detailing patients with
chronic hepatic impairment who have undergone HSCT.
Furthermore, to support patient care, we suggest future
research that pertains to the dosing of antineoplastics in the
setting of hepatic impairment. Toxicity assessment should be
required to report patient baseline hepatic impairment with
clear deﬁnition of the type and degree of liver dysfunction.
Assessment of patient outcome and toxicity with reference
to these parameters should be reported.
MYELOABLATIVE REGIMENS
Myeloablative regimens, especially CY/TBI and BU/CY, are
limited by a high incidence of liver toxicity in the post-
transplant period that may potentially lead to fatal multi-
organ failure [2,28]. SOS is more frequent and more severe in
patients with active inﬂammatory hepatitis with an inci-
dence of approximately 15% to 25% [14]. CY/TBI >14 Gy has
been reported to be associated with the most liver toxicity,
followed by CY/TBI 10 to 14 Gy, targeted BU/CY (TBU/CY), and
ﬂudarabine/BU. Nonmyeloablative regimens are associated
with the least liver toxicity [3].
As individual agents, CY and BU are uncommonly associ-
ated with liver toxicity at standard doses [8]. Currently, there
are only rare case reports of CY-induced hepatocellular ne-
crosis and 2 case reports of cholestatic liver injury related to
BU administration [8,29]. CY is a common component of
conditioning regimenswith the highest incidence of SOS [14].
CY/TBI Regimens
CY/TBI is a common conditioning regimen used before
HSCT that combines CY at a dose of 120 mg/kg administered
in divided doses on 2 consecutive days and TBI, typically in
the range of 10 to 16 Gy [14,30]. The regimen is designed to be
myeloablative to the bone marrow to minimize the risk
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[29]. However, CY followed by TBI appears to be synergistic in
causing sinusoidal injury [14,28,30]. Synergism may be
due to sinusoidal endothelial damage induced by CY metab-
olites followed by further irradiation damage [14]. Another
proposed mechanism is related to glutathione depletion in
hepatocytes and sinusoidal epithelial cells after CY admi-
nistration that leaves the sinusoidal epithelial cells more
vulnerable to TBI [14].
Patients with chronic liver disease who receive CY/TBI
conditioning regimens before transplantation should be
approached with caution. The incidence of SOS increases
with increasing TBI dose when used in combination with CY.
The risk of SOS is approximately 1% with CY/TBI 10 Gy, 4% to
7% with CY/TBI 12 to 14 Gy, and 20% after CY/TBI >14 Gy [2].
Modiﬁcations to both CY and TBI should be considered
empirically, and CY TDM should be used when possible
[4,14,28].
A study conducted by McDonald et al. [28] found that
patients who received CY/TBI before transplant who had
increased exposure to the CY metabolite carboxyethylphor-
amide mustard (CEPM) were more prone to development of
SOS, bilirubin elevation, increased mortality, and decreased
survival. However, patients with lowest exposurewere not at
increased risk for relapse or engraftment failure [28]. It can
be inferred that the dose of CY may be able to be reduced
through the use of TDM in the CY/TBI regimen while still
maintaining equivalent outcomes [14,28]. This ﬁnding is
important for patients with chronic liver disease because CY
is known to be liver toxic at high doses [2,8,14].
BU/CY Regimens
Attempts to reduce the toxicity of the BU/CY regimen
have been reported in the literature, including reversing the
order of administration to CY/BU as well as through phar-
macokinetic targeting of BU and CY [2,4,14,30-33]. When BU
is given before CY, it appears that BU may contribute to
subsequent liver toxicity through glutathione depletion in
hepatocytes and sinusoidal epithelial cells and by altering
the metabolism of CY [14].
The Seattle group reported outcomes of a prospective
clinical trial that tested the hypothesis as to whether
reversed-sequence CY/TBU reduced the frequency and
severity of hepatotoxicity when compared with standard
TBU/CY after allogeneic HSCT [31]. Two patient cohorts were
enrolled. The ﬁrst cohort included patients determined to be
at high risk for toxic SOS (patients with myeloﬁbrosis), and
the second cohort consisted of standard-risk patients with
either myelodysplastic syndrome or acute myelogenous
leukemia. Of note, patients with known hepatic dysfunction,
deﬁned as total bilirubin or aspartate aminotransferase more
than 2 times the upper limit of normal or evidence of syn-
thetic dysfunction or cirrhosis, were excluded from this trial.
Among patients with myeloﬁbrosis, the incidence of SOS
was 0% with CY/TBU conditioning compared with 30% with
TBU/CY (P ¼ .006). Additionally, there were no incidences of
severe SOS in the CY/TBU cohort compared with 11 in-
cidences in the TBU/CY cohort, and day þ100 mortality was
signiﬁcantly reduced (2% versus 12%; P ¼ .01) with CY/TBU.
However, in patients with acute myelogenous leukemia/
myelodysplastic syndrome, the rates of SOS were 6.5% with
CY/TBU versus 9.2% with TBU/CY (P ¼ .61). The cumulative
incidence of relapse for patients with acute myelogenous
leukemia/myelodysplastic syndrome was 44% with CY/TBU
compared with 20% with TBU/CY (P ¼ .008). The 2-yearcumulative incidence of overall survival was not signiﬁ-
cantly affected, and the higher incidence of relapse was
attenuated after adjustment for greater disease risk in the
cohort who received CY/TBU (unadjusted hazard ratio, 2.57,
P ¼ .008; adjusted hazard ration, 2.15, P ¼ .02). Therefore,
administration of CY before BU decreased the frequency of
SOS, potentially related to less variability and production of
toxic CY metabolites [14].
Khawaja et al. [34] conducted a retrospective analysis of 8
patients with X-linked hyper-IgM syndrome who underwent
HSCT at a single center. Three patients had abnormalities on
liver biopsy before HSCT. Patients 6 and 8 had sclerosing
cholangitis and cirrhosis, whereas patient 7 had portal
inﬂammation. Patients 6 and 8 received a BU/CY conditioning
regimen before transplantation, whereas patient 7 received a
regimen consisting of ﬂudarabine, melphalan, and antithy-
mocyte globulin (ATG). Patient 6 died on day þ34 due to
fulminant liver failure, and patient 8 developed SOS requiring
recombinant tissue plasminogen activator on day þ9 and
heparin infusion on day þ11 followed by severe progressive
liver GVHD. The patient died from hemorrhage after liver
biopsy while being assessed for orthoptic liver trans-
plantation. Patient 7 died on day þ87 after capillary leak
syndrome and pneumonitis that progressed to multiorgan
failure. These data suggest that myeloablative regimens may
be too toxic for patients with chronic liver disease.
Therapeutic Drug Monitoring
Clinical data in patients undergoing HSCT with baseline
hepatic impairment have suggested high levels of BUmay be
experienced in patients with abnormal liver function [35,36].
Hassan et al. [35] reported pharmacokinetic parameters for 9
children and 19 adults who received BU before HSCT. A 39-
year-old male patient with unspeciﬁed liver function
disturbance before BU administration was excluded from all
statistical analysis due to extremely high levels of BU with a
mean minimal concentration of 1660 ng/mL measured after
achievement of steady state. Similarly, Sandström et al. [36]
reported that oral clearance (CL/F) was found to be signiﬁ-
cantly correlated with ALT with decreasing CL/F observed
with increasing ALT.
TDM for oral and intravenous BU has been incorporated
into most hematopoietic cell transplant centers; however,
TDM has been limited by logistical challenges and cost [7,32].
Although not well deﬁned, targeted steady-state concen-
tration for BU is typically 800 to 900 ng/mL to prevent under-
dosing and subsequent treatment failure without increasing
the risk of developing SOS to an unacceptable point [7,14].
The use of TDM has led to a reduction of regimen-related
toxicity; however, the incidence of SOS has not been elimi-
nated [31].
TDM has also been conducted using Bayesian models for
CY due to the high variability and liver toxicity associated
with administration [30,32,33]. After an initial 45 mg/kg
dose, the second dose is adjusted based on the ﬁrst day’s
AUCCEPM to target a total exposure that is consistent with
minimal liver toxicity and successful engraftment (AUC
325 mmol/Lh) [32]. Variable exposure to CEPM has been
reported to be reduced from 16-fold to 1.7-fold with the use
of TDM [32]. The mean CY dose has also been reported to
be 28% lower than the standard CY dose used in the CY/TBI
regimen [32]. Additionally, there has been less liver and
kidney injury associated with CY TDM [33]. Because of
the high specialization involved with CY pharmacokinetic
analysis, this method may not be feasible for most centers
Table 1
Reports of HSCT in Patients with Chronic Liver Disease
Reference Patient Population Conditioning Regimen Outcomes
Przepiorka et al. [41] Thirty-six adult patients with CML in second or greater chronic
phase, accelerated phase. Twelve of 36 patients had
transaminases more than twice the upper limit of normal within
1 month pretransplant.
High-dose thiotepa (150-250 mg/m2/d i.v. on days 9, 8,
and 7), BU (1 mg/kg orally every 6 h on days 6, 5,
and 4), and CY (60 mg/kg/d i.v. on days 3 and 2) (TBC)
Patients with transaminase elevation more than twice the upper
limit of normal within 1 month pretransplant were more likely to
develop severe veno-occlusive disease. Risk of severe veno-
occlusive disease was not correlated with positive hepatitis
serology pretransplant.
Dogu et al. [11] Boy age 3.5 yr with X-linked hyper-IgM and grade III liver ﬁbrosis
who underwent allogeneic HSCT.
Treosulfan (12 g/m2/d  3 d) and CY (50 mg/kg/d  4 d) Myeloid engraftment was achieved on day 13. A moderate
increase in liver function test results occurred after the bone
marrow transplant (AST, 473 U/L, ALT, 460 U/L, total bilirubin,
1.49 mg/dL, direct bilirubin, 1.07 mg/dL, g-glutamyltransferase,
95 U/L), which resolved.
Hogan et al. [5] Man age 43 yr with a history of exposure to hepatitis B and C
viruses and excessive alcohol use. Pretransplant liver biopsy
demonstrated chronic hepatitis and moderate inﬂammatory
activity, increased portal ﬁbrosis, and portal-portal bridging.
2 Gy TBI The patient had maximal serum bilirubin level (11 mg/dL) on
day þ5 post-transplant. The patient remained persistently
jaundiced until his death on day þ183 due to liver failure and
relapsed MDS.
Hogan et al. [5] Man age 47 yr with Philadelphia chromosome-positive ALL in ﬁrst
complete remission. The patient had a history of hepatitis B and C,
and a pretransplant biopsy showed severe necroinﬂammatory
changes with portal-portal bridging related to chronic hepatitis.
Lamivudine therapy was initiated before conditioning and
continued through the peritransplantation period.
Flu/TBI Acute hepatic failure developed on day þ52. A transjugular liver
biopsy was performed on day þ54 which showed marked
canlicular cholestasis associated with apoptotic bile duct changes
consistent with GVHD. Maximum bilirubin level was 39 mg/dL,
which occurred preterminally on day þ57.
Hogan et al. [5] Patient age 54 yr with MDS/AML who had a history of excessive
alcohol intake and abnormal AST levels before HSCT. No
pretransplantation biopsy was available.
Flu/TBI Total bilirubin increased to 12.2 mg/dL by day þ9. A liver biopsy
demonstrated diffuse hepatic ﬁbrosis consistent with alcohol-
induced chronic liver disease. The patient died on day þ20 with
hepatic failure.
Khawaja et al. [34] Patient age 13 yr with X-linked hyper-IgM syndrome and severe
liver disease, with diarrhea, chronic cryptosporidial infection,
sclerosing cholangitis, cirrhosis, and chronic pancreatitis before
transplant.
BU (16 mg/kg) and CY (200 mg/kg) The patient died on day þ34 due to fulminant liver failure.
Khawaja et al. [34] Patient age 14 yr with X-linked hyper-IgM syndrome and
cryptosporidial ascending cholangitis with portal inﬂammation
on liver biopsy.
Flu (30 mg/m2) from day 7 to day 3, melphalan
(140 mg/m2) on day 2, and ATG (2.5 mg/kg)
from day 6 to day 2
The patient developed capillary leak syndrome and pneumonitis,
which led to multiorgan failure and death on day þ87.
Khawaja et al. [34] Patient age 14 yr with X-linked hyper-IgM syndrome and
bilateral bronchiectasis and severe liver disease before transplant.
BU (16 mg/kg) and CY (200 mg/kg) The patient developed SOS requiring recombinant tissue
plasminogen activator on day þ9 and heparin infusion on
day þ11. The patient also developed severe progressive liver
GVHD and died from hemorrhage after a liver biopsy while being
assessed for orthoptic liver transplant.
Hamaki et al. [47] Man age 59 yr with stage IV T cell lymphoma and liver cirrhosis
due to HBV infection. Before transplant, serum levels of albumin,
AST, ALT, and total bilirubin were 2.9 g/dL, 44 IU/L, 25 IU/L, and 1.0
mg/dL, respectively. The patient also had red-color sign of
esophageal varices identiﬁed by upper gastrointestinal
endoscopy.
CY 60 mg/kg for 2 d, Flu 25 mg/m2 for 5 d,
and ATG 10 mg/kg for 2 d
The patient’s clinical course was overall uneventful without the
development of severe liver damage. However, the patient
experienced esophageal bleeding on day 64 and hepatic function
deteriorated. He died of hepatic failure on day 68.
Jacobsohn et al. [48] Patient with X-linked hyper-IgM syndrome and documented
cholangiopathy on liver biopsy with the following laboratory
values: total bilirubin, .8 mg/dL, ALT 62 IU/L, alkaline
phosphatase, and 545 IU/L.
Flu (30 mg/m2/d  6 d), BU (.8 mg/kg/dose i.v.
every 6 h  2 d), and ATG (40 mg/kg/d  4 d)
The patient had mixed chimerism 2 years after HSCT and had
evidence of liver recovery based on liver function tests.
Jacobsohn et al. [48] Patient with X-linked hyper-IgM syndrome with documented
cholangiopathy on liver biopsy and the following laboratory
values: total bilirubin, .6 mg/dL, ALT 158 IU/L, alkaline
phosphatase, 462 IU/L, and g-glutamyltransferase, 276 IU/L.
Flu (30 mg/m2/d  6 d), BU (.8 mg/kg/dose i.v.
every 6 h  2 d), and ATG (40 mg/kg/d  4 d)
The patient had 100% donor chimerism at 14months and remains
healthy with no clinical evidence of liver dysfunction.
ALL indicates acute lymphoblastic leukemia; Flu, ﬂudarabine; AML, acute myeloid leukemia; AST, aspartate aminotransferase; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome.
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10% to 20% should be considered in patients for whom a CY-
based regimen is most appropriate [14].
Drug Interactions
BU undergoes extensive hepatic metabolism and is pri-
marily eliminated by the liver [15,17,18]. Studies of the
pharmacokinetic properties of BU have shown a wide range
of intrapatient and interpatient variability. Many factors may
contribute to this variability, including patient age, circadian
rhythm, disease, and concomitant administration of other
agents sharing a common metabolic pathway [35-38].
Azole antifungal agents, which are classiﬁed as potent
CYP3A4 inhibitors, are commonly used in HSCT recipients as
antifungal prophylaxis [14]. Buggia et al. [39] assessed 13
patients undergoing HSCT who received concomitant BU and
itraconazole and compared pharmacokinetic and pharma-
codynamics parameters with 26 matched control subjects
who did not receive an azole antifungal agent as well as to
13 patients who received ﬂuconazole as antifungal prophy-
laxis. Their ﬁndings demonstrated that BU clearance was
decreased by 20% on average in patients receiving itracona-
zole compared with control patients and patients receiving
ﬂuconazole (P < .01).
Hassan et al. [40] studied the pharmacokinetics of high-
dose BU used during conditioning before bone marrow trans-
plantation in 17 patients using deuterium-labeled BU. Their
ﬁndings demonstrated that patientswho received concomitant
phenytoin, a potent CYP3A4 inducer, demonstrated signiﬁ-
cantly higher clearance (3.32  .99 [mean  standard devia-
tion] mL/min/kg), a lower area under the concentration time
curve (5412  1534 ngh/mL; corrected for dose/kg), and a
shorter elimination half-life (3.03 .57 hours) for the last dose
of deuterium-labeled BU (dose 16) as compared with the ﬁrst
dose (2.80  .78 mL/min/kg, 6475  2223 ngh/mL, and
3.94  1.10 hours, respectively).
Thiotepa/BU/CY Regimen
High-dose thiotepa, BU, and CY have been studied to
determine if the addition of a third alkylating agent would
improve outcome without increasing toxicity [41]. Prze-
piorka et al. [41] evaluated the thiotepa/BU/CY regimen in 36
patients with chronic myelogenous leukemia in second or
greater chronic phase, accelerated phase, or blast crisis who
underwent HSCT (Table 1). Within their patient population,
12 patients had transaminases that weremore than twice the
upper limit of normal within 1 month pretransplant. The
most common regimen-related toxicities weremucositis and
elevated liver enzymes, and 22% of patients developed severe
veno-occlusive disease. Patients with transaminase elevation
more than twice the upper limit of normal within 1 month
pretransplant were more likely to develop severe SOS;
however, risk of severe SOS was not correlated with positive
hepatitis serology before HSCT.
Treosulfan-Based Conditioning
Treosulfan is a hydrophilic, immunosuppressive, and
myeloablative alkylating agent that is similar to BU but with
a more favorable toxicity proﬁle [11]. Dogu et al. [11]
described a case report of a 3.5-year-old boy with X-linked
hyper-IgM who presented for allogeneic HSCT. The patient
was found to have abnormal liver enzymes and chronic liver
disease together with hepatosplenomegaly on ultrasono-
graphic evaluation of the liver. A conditioning regimen of
treosulfan and CY was selected for the patient (Table 1). Thisregimen had previously been studied in 18 patients with
hematologic malignancies and in a pediatric patient popu-
lation with various malignancies and was found to be less
toxic than BUwhen used in similar combination [42,43]. This
patient achieved myeloid engraftment on day þ13 and had a
moderate increase in liver function tests post-transplant,
which resolved.
REDUCED-INTENSITY/NONMYELOABLATIVE REGIMENS
Reduced-intensity conditioning regimens have proven to
be a less toxic modality for conditioning before transplant
and have allowed transplant to be offered to older patients
with more comorbidities. Parmar et al. [44] conducted a
phase I/II Bayesian adoptively randomized study to deter-
mine the optimal dose, dosing schedule, and efﬁcacy of
intravenous BU in combination with ﬂudarabine before
HSCT. BU doses were administered up to 11.2 mg/kg without
pharmacokinetic monitoring. Relapse rates in the trial were
43% and were associated with dose intensiﬁcation, but
toxicity was not increased. There was no increase in liver
toxicity observed. Transaminitis occurred in 35% of patients
post-transplant, and 1 patient developed SOS at day þ67
with altered mental status, hepatic encephalopathy, and
raised transaminitis. This approach is worth investigating in
patients with chronic liver disease but in the absence of data
cannot be currently recommended in all patients.
Fludarabine has been reported to be marginally associ-
ated with an increased risk of developing jaundice post-
transplant [5]. Hepatotoxicity was not initially reported to
be a prominent adverse effect after administration in early
trials [5]. Hogan et al. [5] described 193 patients who were
treated with allogeneic transplant after nonmyeloablative
conditioning between 1997 and 2002. Before transplant,
patients were evaluated for liver dysfunction, and patients
with evidence of liver disease underwent liver imaging and
biopsy, as clinically indicated. Fifty-one patients developed
jaundice, of which 18 had liver histology. Three patients
were known to have chronic liver disease before transplant
and developed serious liver dysfunction after transplant
(Table 1). Exposure to ﬂudarabine was determined to be
potentially associated with hyperbilirubinemia, possibly due
to sensitization of the liver to injury from either TBI or allo-
geneic cells [5].
Melphalan is not thought to be hepatotoxic at standard
doses. Mild, transient elevations of aminotransferases and
bilirubin have been infrequently reported with high-dose,
single-agent melphalan administration (140 mg/m2)
[8,45,46]. In combination with other cytotoxic agents,
melphalan has been associated with development of SOS at
high doses but at a lesser incidence and severity than with
BUeCY combinations [8].
Fludarabine-Based Regimens
There have been reports of successful allogeneic trans-
plants in patients with chronic liver disease who received
nonmyeloablative regimens using ﬂudarabine [47,48].
Hamaki et al. [47] described a 59-year-old manwith stage IV
T cell lymphoma and liver cirrhosis due to HBV infection
who underwent HSCT using a regimen consisting of Cy,
ﬂudarabine, and ATG (Table 1). The patient had moderately
impaired liver function with mild cirrhotic changes identi-
ﬁed pathologically. Pharmacokinetic studies were altered.
The elimination half-lives of CY’s unmetabolites were 8.4
and 12.4 hours on the ﬁrst and second day, respectively. Vd
of 2-F-ara-A (9-beta-D-arabinofuranyosyl-2-ﬂuoroadenine)
M.N. Bodge et al. / Biol Blood Marrow Transplant 20 (2014) 622e629628was 31.0 L/m2 on the ﬁrst day of administration. Cmax and
area under the curve with the ﬁfth administration were
signiﬁcantly higher than those with previous administra-
tions. The patient did not experience severe toxicity from
the conditioning regimen but did experience esophageal
bleeding on day þ64 and hepatic function deteriorated. He
died of hepatic failure on day þ68.
Jacobsohn et al. [48] described 2 patients with X-linked
hyper-IgM syndrome and documented cholangiopathy on
liver biopsy who underwent HSCT from HLA-matched sib-
lings using a conditioning regimen of ﬂudarabine, BU, and
ATG (Table 1). The ﬁrst patient had mixed chimerism 2 years
after HSCT and had evidence of liver recovery based on liver
function tests. The second patient had 100% donor chime-
rism at 14 months and remains healthy with no clinical ev-
idence of liver dysfunction. These reports demonstrate that
ﬂudarabine-based conditioning regimens may be accept-
able in patients with mild-to-moderate liver impairment.RECOMMENDATIONS
For patients with inﬂammatory hepatitis who undergo
transplant, we strongly recommend modifying the condi-
tioning regimen by reducing the dose of CY, substituting a
less liver-toxic drug for CY, or selecting a nonmyeloablative
regimen. For patients with HBV infection, we recommend
considering antiviral treatment with lamivudine beginning
2 weeks before the conditioning regimen [14].
For CY/TBI regimens, we recommend the total CY should
range from 90 to 110 mg/kg and TBI not exceed 12 Gy [2]. We
also recommend that an empiric 10% to 20% reduction in CY
dosing be considered for patients in whom a CY-based
regimen is required [14]. For BU/CY regimens, we recom-
mend administering CY before intravenous BU or delaying
the administration of CY by 1 to 2 days after BU adminis-
tration [31]. We strongly recommended use of TDM for both
BU and CY whenever possible.
It is preferable to use a reduced-intensity regimen or a
nonmyeloablative regimen when possible, although there
are no data to recommend a speciﬁc regimen. When a
myeloablative regimen is used, we recommend consider-
ation of SOS prophylaxis with ursodiol 300 mg 3 times daily
beginning 14 days before initiation of the conditioning
regimen [15]. We also recommend discontinuing all other
hepatotoxic medications if possible [15].CONCLUSIONS
Allogeneic transplant offers the potential for cure for a
variety of malignant and nonmalignant disease states but
comes with a high risk [47]. Standard myeloablative regi-
mens may be too toxic for patients with chronic liver disease
due to the potential for SOS and other liver complications
post-transplant [15]. However, nonmyeloablative regimens
may prove to be a feasible option for patients with hepatic
impairment [34,47,48]. Thoughtful consideration of patient
factors in conditioning regimen selection, minimization of
hepatotoxins, aggressive ﬂuid management, and usage of
prophylactic ursodiol may lead to improved outcomes for
patients with chronic hepatic impairment who undergo
transplantation [15]. Additional literature detailing out-
comes of patients with chronic liver disease who undergo
HSCT is ultimately needed to better elucidate the best con-
ditioning regimens and supportive care measures that may
lead to treatment optimization.ACKNOWLEDGMENTS
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